Positive effect of if-channel’s blocker ivabradine therapy in a patient with ischemic chronic heart failure with preserved left ventricle ejection fraction and hereditary thrombophilia (clinical case)

2019

КардиоСоматика, Vol 10, Iss 3, Pp 79-84 (2019)

Chronic heart failure is one of the leading causes of mortality among patients with cardiovascular diseases. Current therapeutic methods for treating patients with chronic heart failure do not always provide a significant improvement in main intermediate and final outcomes. According to the neurohumoral theory of chronic heart failure development, an antagonism of the sympathoadrenal system with b-blockers is pathogenetically substantiated, and the drugs of this group are one of the first-line treatment for chronic heart failure. The selection of heart rate-reducing therapy in patients with chronic heart failure caused by ischemia, can often be difficult due to development of b-blockers side effects, b-blockers intolerance and/or due to the presence of contraindications at severe comorbid pathology. This article presents a clinical case of an effective administration of ivabradine, a drug of if-channel inhibitors group, in combination with b-blockers to a patient with chronic heart failure with a preserved ejection fraction.

article

English
Russian

Concilium Medicum, 2019.

хроническая сердечная недостаточность, хроническая сердечная недостаточность с сохранной фракцией выброса, ишемическая болезнь сердца, ивабрадин, частота сердечных сокращений, тахикардия, Diseases of the circulatory (Cardiovascular) system, RC666-701, Diseases of the endocrine glands. Clinical endocrinology, RC648-665